PM
CRL icon

Precept Management’s Charles River Laboratories CRL Stock Holding History

Precept Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,000
Closed -$1.65M – 63
2021
Q3 		$1.65M Buy
+4,000
New +$1.66M 0.77% 40
2020
Q4 		– Sell
-100,000
Closed -$22.6M – 61
2020
Q3 		$22.6M Buy
+100,000
New +$20.8M 5.56% 3
2020
Q2 		– Sell
-50,000
Closed -$6.31M – 99
2020
Q1 		$6.31M Buy
+50,000
New +$7.5M 0.78% 24

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Precept Management's CRL Position: Q1 2022 in Review

Precept Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 13,100 shares — an estimated $4.94M sold.

Precept Management first reported a position in CRL in Q1 2019 and held it in 12 quarters. The position peaked at $22.5M in Q4 2020. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Precept Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Precept Management sold 13,100 Charles River Laboratories shares in Q1 2022, an estimated $4.94M.
  • Precept Management first reported a position in Charles River Laboratories in Q1 2019 and held it in 12 quarters.
  • Precept Management's Charles River Laboratories position peaked at $22.5M in Q4 2020.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Precept Management's 13F filing for Q1 2022, filed 16 May 2022.